Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RSV inhaled powder vaccine
- Development stage
- Preclinical
- Lead developer
- TechnoVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Inhalation
01
Overview
The RSV inhaled powder vaccine is a preclinical-stage vaccine candidate developed by TechnoVax for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine utilizes TechnoVax's Virus-Like Particle (VLP) platform, which creates non-infectious particles that structurally mimic the native virus to stimulate an immune response without the risk of viral replication. A key feature of this candidate is its formulation as a dry powder for intrapulmonary delivery via inhalation. This approach is designed to induce mucosal immunity at the site of infection while offering advantages such as shelf-stability at room temperature and the potential for self-administration, bypassing the need for traditional cold chain logistics and needle-based injection. TechnoVax has partnered with a pulmonary drug delivery company to optimize the inhaled delivery format.
- Other names
- RSV Inhaled Powder VLP Vaccine
02
Targets
B-cell receptor specific for Respiratory Syncytial Virus Fusion and Attachment proteinsRSV F (Respiratory syncytial virus fusion protein)T-cell receptor recognizing Respiratory Syncytial Virus Fusion and Attachment protein-derived peptidesRSV G (Respiratory syncytial virus attachment glycoprotein)
Beyond the preview
Go deeper on RSV inhaled powder vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RSV inhaled powder vaccine.